These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 30756134)
1. Targeting the immune system in the treatment of bipolar disorder. Rosenblat JD Psychopharmacology (Berl); 2019 Oct; 236(10):2909-2921. PubMed ID: 30756134 [TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Rosenblat JD; Kakar R; Berk M; Kessing LV; Vinberg M; Baune BT; Mansur RB; Brietzke E; Goldstein BI; McIntyre RS Bipolar Disord; 2016 Mar; 18(2):89-101. PubMed ID: 26990051 [TBL] [Abstract][Full Text] [Related]
3. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. Ayorech Z; Tracy DK; Baumeister D; Giaroli G J Affect Disord; 2015 Mar; 174():467-78. PubMed ID: 25553408 [TBL] [Abstract][Full Text] [Related]
7. [Non-conventional pharmacological agents for the treatment of bipolar disorder: Α systematic review of the evidence]. Fountoulakis KN; Balaris D; Nikolaou V; Νimatoudis J Psychiatriki; 2016; 27(4):253-263. PubMed ID: 28114089 [TBL] [Abstract][Full Text] [Related]
8. Immune-based strategies for mood disorders: facts and challenges. Colpo GD; Leboyer M; Dantzer R; Trivedi MH; Teixeira AL Expert Rev Neurother; 2018 Feb; 18(2):139-152. PubMed ID: 29179585 [TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review. Ruiz-Sastre P; Gómez-Sánchez-Lafuente C; Martín-Martín J; Herrera-Imbroda J; Mayoral-Cleries F; Santos-Amaya I; Rodríguez de Fonseca F; Guzmán-Parra J; Rivera P; Suárez J Prog Neuropsychopharmacol Biol Psychiatry; 2024 Aug; 134():111056. PubMed ID: 38879067 [TBL] [Abstract][Full Text] [Related]
10. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Rosenblat JD; McIntyre RS Acta Psychiatr Scand; 2015 Sep; 132(3):180-91. PubMed ID: 25772638 [TBL] [Abstract][Full Text] [Related]
11. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Popovic D; Reinares M; Goikolea JM; Bonnin CM; Gonzalez-Pinto A; Vieta E Eur Neuropsychopharmacol; 2012 May; 22(5):339-46. PubMed ID: 22000157 [TBL] [Abstract][Full Text] [Related]
12. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Sarris J; Mischoulon D; Schweitzer I Bipolar Disord; 2011; 13(5-6):454-65. PubMed ID: 22017215 [TBL] [Abstract][Full Text] [Related]
13. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Soczynska JK; Kennedy SH; Alsuwaidan M; Mansur RB; Li M; McAndrews MP; Brietzke E; Woldeyohannes HO; Taylor VH; McIntyre RS Bipolar Disord; 2017 May; 19(3):198-213. PubMed ID: 28599348 [TBL] [Abstract][Full Text] [Related]
14. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression. Bauer IE; Green C; Colpo GD; Teixeira AL; Selvaraj S; Durkin K; Zunta-Soares GB; Soares JC J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549489 [TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy, acceptability, and tolerability of adjunctive anti-inflammatory agents on bipolar disorder: A systemic review and network meta-analysis. Xu H; Du Y; Wang Q; Chen L; Huang J; Liu Y; Zhou C; Du B Asian J Psychiatr; 2023 Feb; 80():103394. PubMed ID: 36525766 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients. Sayana P; Colpo GD; Simões LR; Giridharan VV; Teixeira AL; Quevedo J; Barichello T J Psychiatr Res; 2017 Sep; 92():160-182. PubMed ID: 28458141 [TBL] [Abstract][Full Text] [Related]